Gore Acquires Conformal Medical and Its Foam-Based CLAAS Left Atrial Appendage Occluder to Challenge Boston Scientific and Abbott

Gore Announces Collaboration withConformal MedicalFinalized and SignedAcquisitionAccording to the agreement, the acquisition price was not disclosed by Gore. However, based on last year...Conformal MedicalCompleted$32 millionThe D-round extension financing, the acquisition price this time will not be low, possibly up to more than one billion US dollars.

Gore stated: This timeThe acquisition has driven Gore's expansion into adjacent endovascular therapy fields and reflects Gore’s long-term commitment to the development and investment in cutting-edge medical technologies. Over the past 50 years, Gore has developed numerous innovative products within its cardiac, vascular, and surgical solutions portfolio.

Executive Evaluation

"The CLAAS Left Atrial Appendage Occluder in the research phase represents a science-driven, transformative innovation, reflecting our long-term commitment to improving patient care. It seamlessly integrates with our endovascular product portfolio and serves as a strong complement to our existing cardiac offerings. As a privately held company founded on scientific innovation, Gore continues to seek opportunities and collaborations that expand our ability to improve lives through the work of our various business units, including enhancing our capacity to serve clinical professionals and improve patient outcomes."

---Bret Snyder Chairman of the Board and Chief Executive Officer of Gore Company

"We are thrilled to partner with a company that shares our belief that the investigational CLAAS may become a transformative solution in stroke prevention. As we advance this therapy through clinical and regulatory processes, and ultimately bring it to patients around the world, our shareholders will come to appreciate the value of this partnership. This collaboration combines Conformal's deep expertise in LAAO with Gore's world-class capabilities in technology development, distribution, and operations. We will be able to leverage Gore’s global reach to further our mission of shaping the future of stroke prevention."

---James Reinstein  Chairman and Chief Executive Officer of Conformal Medical

CurrentlyConformal MedicalLeft Atrial Appendage OccluderCLAASAlready completed 500 IDE clinical enrollments (the entire clinical study requires 1600 patients), and after being acquired by Gore, the clinical process is expected to accelerate (with sufficient funding).

Gore AcquisitionConformal MedicalIn addition to being able to expandBeyond the product line in the field of endovascular treatment, more importantly,CLAASExcellent Clinical Data and Large ScalePatients with non-valvular atrial fibrillation (AFib) (12 million in the U.S. alone)Patients with atrial fibrillation, while Boston Scientific promotes a one-stop solution for atrial fibrillation, also drives the rapid adoption of left atrial appendage closure devices.）。

The year before lastConformal MedicalPublishCLAASCompared with Watchman FLXA comparative study of acute thrombosis in an ex vivo blood circulation model showed: Conformal Medical outperformed Boston Scientific.Watchman FLX。

CLAASAdoptFoam Structure Design, only two sizes are needed to adapt to the vast majority of left atrial appendage anatomical shapes. Its simplified size selection and occlusion effect confirmation features can accelerate the clinical shift towards ICE-guided occlusion procedures, thereby avoiding the use of intraoperative transesophageal ultrasound and general anesthesia. This innovation is expected to drive clinical practice towardsSingle-operator, minimally invasive treatmentModel Evolution.

• Minimum imaging requirements, without general anesthesia

• Seals even when off-axis

• In the absence of TEE, perform surgery based on ICE evaluation.

• Consistent Sealing Effect
  

• Foam matrix with a compliant skeleton conforms to the anatomy of all patients.

• Surface Anti-Thrombosis

• ePTFE-covered surface, with no connecting screws

• Non-invasive Delivery

• The front end of the foam matrix can provide a bumper-like function during delivery.

• Evaluate at the final position before release.

• Tension-Free Delivery System

• Short Landing Zone and Secure Anchoring

• Minimum 10mm landing zone

• Suitable for most LAA anatomies

• Two rows of 20 anchors for a more secure fixation

CLAASPerformanceIndication

Conformal Medical